BioLargo (BLGO) AI Stock Analysis

• Market Cap: $60.88M
• Dividend Yield: N/A
• Average Volume (3M): 410.05K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.30
• Revenue Growth: 22.97%
• EPS Growth: 17.32%
• Country: US
• Employees: 40
• Sector: Basic Materials
• Sector Strength: 71
• Industry: Chemicals
• EPS (TTM): N/A
• Shares Outstanding: 304,850,980
• 10 Day Avg. Volume: 415,195
• 30 Day Avg. Volume: 410,053
• PEG Ratio: 0.60
• Price to Book (P/B): 8.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.76
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 0.90
• Enterprise Value/Gross Profit: 8.77
• Enterprise Value/Ebitda: -3.84
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: $0.00 ▼(-100.00%Downside)

BioLargo's revenue growth is a positive indicator, but consistent losses and negative cash flow are significant concerns impacting financial stability. The technical indicators suggest bearish momentum, while valuation metrics show challenges due to negative earnings.

BioLargo Business Overview & Revenue Model

Company Description

BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

How the Company Makes Money

BioLargo makes money through the sale and licensing of its proprietary technologies and products. Key revenue streams include direct sales of their water treatment systems and odor control products to industrial and municipal clients, as well as licensing agreements for the use of their patented technologies. The company also generates income through strategic partnerships with other organizations that leverage BioLargo's innovations to enhance their own product offerings. Additionally, consulting services provided by BioLargo Engineering, Science & Technologies (BLEST) contribute to the company's revenue by offering specialized expertise in environmental engineering projects.

BioLargo Financial Statement Overview

Summary

BioLargo exhibits strong revenue growth from $1.86M in 2019 to $17.78M in 2024, but faces challenges with profitability and cash flow. Net losses persist with a $2.40M loss in 2024 and operational cash flow remains negative, indicating financial management challenges.

Income Statement

BioLargo has demonstrated significant revenue growth, increasing from $1.86M in 2019 to $17.78M in 2024, showing a strong upward trajectory. However, the company remains unprofitable with consistent net losses, including a net loss of $2.40M in 2024. The gross profit margin has improved but remains volatile. EBIT and EBITDA margins remain negative, indicating operational challenges.

Balance Sheet

BioLargo's financial stability is supported by a strong equity position with a debt-to-equity ratio significantly improved over the years, now at 0.17. The equity ratio is healthy at 84.18%. However, the company has high leverage in earlier years and a history of negative net debt, indicating potential liquidity risks.

Cash Flow

Operating cash flow has been consistently negative, reflecting ongoing operational cash burn. Free cash flow growth has not been positive, and the free cash flow to net income ratio remains challenging. While financing activities have supported cash needs, sustained negative cash flows pose a risk to long-term financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.29M	17.78M	12.23M	5.88M	2.53M	2.43M
Gross Profit	7.10M	7.85M	6.15M	2.86M	1.10M	1.23M
EBITDA	-5.13M	-4.06M	-4.19M	-5.10M	-6.70M	-7.83M
Net Income	-3.15M	-2.40M	-3.50M	-4.50M	-7.38M	-10.47M
Balance Sheet
Total Assets	10.51M	10.51M	8.21M	4.86M	3.02M	4.94M
Cash, Cash Equivalents and Short-Term Investments	2.56M	3.55M	3.54M	1.85M	962.00K	716.00K
Total Debt	1.43M	2.55M	1.70M	1.47M	1.13M	2.67M
Total Liabilities	2.05M	4.46M	4.00M	2.85M	2.09M	5.18M
Stockholders Equity	7.61M	8.85M	6.84M	4.88M	4.65M	3.86M
Cash Flow
Free Cash Flow	-5.89M	-4.44M	-2.84M	-3.03M	-3.97M	-4.18M
Operating Cash Flow	-5.52M	-3.21M	-2.37M	-2.76M	-3.94M	-4.15M
Investing Cash Flow	-454.00K	-1.32M	-478.00K	-271.00K	-34.00K	-123.00K
Financing Cash Flow	4.22M	4.44M	4.66M	3.96M	4.23M	4.34M

BioLargo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.21, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.74 is Neutral, neither overbought nor oversold. The STOCH value of 39.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.

BioLargo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VHI	73 Outperform	$516.66M	4.44	11.76%	1.77%	7.82%	19465.71%
LXU	55 Neutral	$583.65M	―	-5.28%	―	-4.23%	-259.01%
RYAM	54 Neutral	$276.45M	―	-10.12%	―	2.20%	34.71%
FF	54 Neutral	$176.97M	11.43	-3.29%	5.75%	-33.92%	-58.53%
ORGN	53 Neutral	$84.36M	―	-26.63%	―	-11.91%	-26768.00%
BLGO	49 Neutral	$60.88M	―	-40.03%	―	22.97%	17.32%
Sector *	43 Neutral	AU$1.41B	-6.02	-40.74%	3.99%	-3.45%	-41.76%

BioLargo Corporate Events

BioLargo Approves Proposals at Annual Meeting

At its 2025 annual stockholder meeting on June 19, 2025, BioLargo, Inc. announced the approval of all proposals, including the election of board members and the authorization for a potential reverse stock split. Although the reverse stock split was approved, the board has no immediate plans to implement it, intending to do so only if necessary for uplisting to a national exchange. CEO Dennis Calvert highlighted the company’s strategic positioning and readiness to expand its market reach and attract institutional investors when conditions are favorable.

BioLargo Presents at Webcast Investor Conference

BioLargo, Inc. presented a slide presentation at a webcast investor conference on May 15, 2025. The information shared during this event is not considered filed with the SEC and the company does not have an obligation to update it, although it may choose to do so in the future.